Bill Anderson, the Chief Executive Officer of Bayer, is conducting a close assessment of the pharmaceutical pipeline in the company since the global life sciences firm is under intense scrutiny from regulators in major markets. The move is happening at a very critical time for Bayer since the firm is committed to winning back confidence from regulators, investors, and healthcare partners even as innovation becomes the focus for the long-term strategy.
Pharmaceuticals have always been a driving force for growth at Bayer. This is because it has major blockbusters pertaining to cancer, cardiology, and women’s healthcare. But today, it faces more stringent regulatory approval procedures, shifting norms for safety, and greater pressure from regulators across Europe and America. Such challenges have led Bayer to think differently about how it can transition medications from development to late stages of clinical development.
Bill Anderson has reinforced the notion that the pipeline review is not about inhibiting innovation, but about refocusing it. So, according to top executives, Bayer is focusing on assets that have compelling clinical profiles, are sharply differentiated, and offer a viable approach to treat pressing unmet medical needs. Even evaluating immature projects, which may no longer be in sync with what is expected by regulatory authorities, is a part of Bayer’s strategy of optimizing success rates and capital returns.
There has been more regulatory attention globally, especially concerning safety within the pharma segment, trial integrity, as well as surveillance post-launch. For a company like Bayer, this has led to more interactions with regulatory bodies like the European Medicines Agency or the Food and Drug Administration in the US. Bayer is said to be enhancing its compliance processes within its business, improving data management, and making use of digital technology for more effective, quicker reporting.
It would not be right, however, without mentioning another very important element of the review, which has to do with the cancer pipeline of Bayer, recognized as a key driver of growth for the future. Bayer has a range of targeted treatments for cancer, with a strong focus on precision medicine, although increasingly, what’s being demanded from the regulator’s perspective is solid evidence for long-term outcomes for patients.
Besides these regulatory considerations, the product review process is also affected by commercial imperatives. Pressures exerted by the government and the insurance industry with respect to prices have forced the industry into realizing the importance of proving value. Bayer is now giving more importance to products that could provide quantifiable benefits with respect to the improvement of the quality of life and reduction in hospitalization or reductions in healthcare costs.
The role of organizational culture during this phase of scrutiny has also been emphasized by Bill Anderson. He has urged Bayer’s R&D and regulatory groups to have more collaboration and overcome organizational silos that sometimes hinder decisions or trigger compliance risks. There have been efforts to make internal processes more efficient to ensure that possible regulatory risks are earlier evaluated and remedied to prevent expensive fixes later down the road.
However, Bayer is very optimistic about the future potential of its pharmaceutical operations. The company continues to make significant investments in research and development partnerships and in innovative technologies in the fields of cell and gene therapies. The management at Bayer is of the opinion that a prudent assessment of the company’s pipeline and pro-active engagement with the regulators can ultimately improve the company’s credibility and competitiveness in the global environment. As regulatory guidelines become increasingly stringent, Bayer’s strategy under Bill Anderson expresses a future vision of focusing and being more transparent and accountable. Although this is obsessed with challenges in the short term, Bayer considers this scrutiny an opportune time to shape and develop a stronger pharma pipeline in ways that meaningfully innovate and meet only the highest standards.
